Biotech Values

[lojjm]

Getting caught back up on GENR --

Dew and others, hope you don't mind a request for a pointed update on GENR. I took the plunge with GENR some time ago, based on the promised efficacy of squalamine and the appeal of systemic delivery (which seemed a huge competitive advantage to me at the time, and still does). And GENR's stock price ticked up dramatically when the Mexican study showed a third of patients with IMPROVED vision, which seemed to further set it apart from the competition.

I don't follow this message board closely, but I did note when Dew turned bearish a few months ago because newer testing data showed mere stabilization of vision (and none of the improved vision found in the Mexican study). But Dew's bearishness seems to have survived the most recent data that seems to confirm improved vision for a third of patients (as I recall the Mexican study also found a third OF PATIENTS improving).

Why should we not have the same or more enthusiasm for our investment in GENR now as we did when the Mexican study came out?

Regards,

lojjm